Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts
NCT03085004Phase 3Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Apr 2019
- Primary completion
- Dec 2025
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Paclitaxel Micelles for Injection and gemcitabine in pancreatic cyst (2 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Percentage of subjects achieving complete cyst resolution at 12 months and Percentage of subjects achieving complete cyst resolution at 24 months. Started Apr 2019; status: terminated.
02
Drugs
Paclitaxel Micelles for Injectiongemcitabine
03
Conditions
pancreatic cyst
Beyond the preview
Go deeper on NCT03085004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085004.